A Unique Class Of Preferreds: The Perfect Income Security? [View article]
Thanks so much for your kind words Bob. It's easy to push normal dividend stocks as there really isn't much effort required in "discovering" them. I have long thought that finding "out of the box" opportunities will pay off in the long run.
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
Very true, modern computing has allowed much of the inefficiency to be "arb'd" out. As these securities are not based on NAV, I am pretty comfortable owning them. The only realistic risk that I can see is your risk to call depending on the premium paid. That being said, I am a big fan of purchasing CEF's at the low end of their historical premium/discount range.
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
Thanks for the heads-up on Source Capital. The yield is about 7% at current prices but you have over 20% call risk. Compare that to say, the TYG preferred which has a 6% yield (monthly payouts!) and a call risk of only 4.3%. In coming up with this article I was also looking to find plays that limit downside. Personally, I would not take the 20% call risk for the extra 1% yield.
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
Your comment about Auction Rate Preferreds is a good one. The advantage here is that the fund MUST redeem if the ratio falls below 2:1 and their collateral is common stock which, of course, is VERY liquid. TYG, for example, recently had a coverage ratio of over 10:1!
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
I think that this is a stock worth watching as the revenue will ramp up allowing price appreciation. They are trying to get an indication approved for hip procedures which far outnumber knee procedures. This is a growth story not a value proposition. In order to think this is a good buy you need to buy into the growth story.
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
Price of a stock is irrelevant. You can have a $10 billion company with a $1 stock and a $10 million company with a $1 stock. All that matters is market cap...
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
I took a cursory glance at Titan. I could be wrong but it seems to me as they do not have any products currently being marketed. This is a significant difference from MAKO which sells FDA approved products every quarter.
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
That may be true but the MAKO procedure lowers procedure costs and recovery costs/time. I think this could be a plus especially in light of the number of total knee replacements performed each year.
SodaStream Fizzling Out, Time to Buy [View article]
By the way, something cannot be very unique. If it is unique then it is one of a kind. Something cannot be "very" one of a kind. I have also written about SODA. The issue is whether people really want to make their own soda. Citing a $500 billion market is somewhat misleading as there is a great deal of brand loyalty under the Pepsi and Coca-Cola umbrellas. SODA's attainable market size in the US very much remains to be seen.
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
A Unique Class Of Preferreds: The Perfect Income Security? [View article]
Biotech Clinical Trials Update [View article]
Biotech Clinical Trials Update [View article]
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
George Soros Is Decreasing His Stake in These Top Stocks [View article]
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
MAKO Surgical's Proven Model Signals Profits Ahead [View article]
SodaStream Fizzling Out, Time to Buy [View article]
Echo Therapeutics: The Next 10-Bagger [View article]
Echo Therapeutics: The Next 10-Bagger [View article]
Rebutting 'The Short Case for Zalicus' [View article]